The ARTEMIS Study

Status:

Sponsor: Adverum

Trial Summary


This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56.

Safety, tolerability, and efficacy will be evaluated throughout the study.

Condition(s) being studied:​

Exudative Macular Degeneration

Trial date:

Primary Completion (Estimated)

2026-12-22

Study Completion (Estimated)

2030-11-23

Explore Our Active Trials

  • The Izervay Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an…

  • The ASP7317 Study

    July 23, 2026

    Sponsor: Astellas Trial Summary Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina – the light-sensitive part at the back of the eye. There are 2 types of…

  • The EVOLVE Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is focused on people with Stargardt disease (STGD) and STGD-like macular dystrophies, inherited retinal conditions that affect the macula and can lead to progressive loss of central vision. STGD is most commonly caused by changes in the ABCA4 gene, while STGD-like conditions are linked…

  • The SIENNA Study

    July 22, 2026

    Sponsor: REGENERON Trial Summary This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition…